Erasca (ERAS) Oppenheimer 36th Annual Healthcare Life Sciences Conference summary

Strategic pipeline overview

• Focus on targeting RAS-driven cancers with two lead programs: ERAS-0015 (pan-RAS molecular glue) and ERAS-4001 (pan-KRAS switch II pocket inhibitor).

• ERAS-0015 leverages high cyclophilin A binding affinity, aiming for best-in-class potency and improved pharmacokinetics.

• ERAS-4001 is designed for high KRAS selectivity, potentially widening the therapeutic window and enabling combination therapies.

• Both orthogonal mechanisms may allow future combination strategies.

• The company holds US composition of matter IP for ERAS-0015 through 2043.

Clinical development and data updates

• AURORAS-1 (ERAS-0015) is enrolling rapidly, with a first-half update expected to include safety, PK, and efficacy data across multiple tumor types.

• BOREALIS-1 (ERAS-4001) is ongoing, with a second-half update planned; both trials are all-comer studies for RAS mutations.

• Early clinical data for ERAS-0015 show activity at doses tenfold lower than competitors, with favorable safety and linear PK.

• No dose-limiting toxicities observed for ERAS-0015 as of early January data cutoff.

• Dose expansion and combination studies are planned for 2027.

Differentiation and future directions

• ERAS-0015 demonstrates higher cell-based potency and improved tumor biodistribution, potentially widening the therapeutic window.

• Lower drug load and better PK may reduce GI and skin toxicities compared to competitors.

• ERAS-4001 is built on a different scaffold than other pan-KRAS inhibitors, which may avoid some class liabilities.

• Both assets are positioned to address major solid tumors (PDAC, CRC, NSCLC) and long-tail opportunities, with flexibility to adapt as the field evolves.

• A bispecific EGFR antibody (ERAS-12) is in preclinical development, targeting enhanced activity through dual domain binding.